Clinical Trial

Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

Study acronym: OC-POP-PT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-16.
Status change: Not Yet Recruiting → Recruiting 2025-07-08
Trial Details
NCT Number NCT06839144
Lead Sponsor Tel-Aviv Sourasky Medical Center
Collaborators: National Cancer Institute (NCI), The Chaim Sheba Medical Center
Conditions Ovarian Cancer, Ovarian Cancer Metastatic Recurrent
Enrollment 60 participants
Start Date 2025-03-12
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-11